Improved EQ-5D and EQ-5D VAS ( p < 0.001 ) and FACIT-Fatigue ( p < 0.001 ) scores were also observed for golimumab + MTX-treated patients at Week 12 , Week 16 , and Week 24 , and greater proportions of golimumab + MTX-treated patients had clinically meaningful improvements in these measures .